Lv31
360 积分 2023-08-14 加入
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
1小时前
待确认
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
1小时前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
1小时前
已完结
Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis
1个月前
已完结
A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular Carcinoma
1个月前
已完结
Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
1个月前
已完结
Immunotherapy at all stages of hepatocellular carcinoma
1个月前
已完结
Watch-and-Wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma：a propensity score-matching comparative study
2个月前
已完结
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
3个月前
已完结
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC
3个月前
已完结
皖公网安备34019202002308
